Clinical Trials List
2021-06-01 - 2023-06-28
Phase II
Terminated3
ICD-10K74.4
Secondary biliary cirrhosis
ICD-10K75.81
Nonalcoholic steatohepatitis (NASH)
ICD-10K76.0
Fatty (change of) liver, not elsewhere classified
ICD-10K76.89
Other specified diseases of liver
ICD-10R16.2
Hepatomegaly with splenomegaly, not elsewhere classified
ICD-9571.8
Other chronic nonalcoholic liver disease
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Yi-Cheng Chen 無
- 鄭雅婷 無
- I-Shyan Sheen 無
- 曾振輝 無
- 戴達英 無
- Chao-Wei Hsu 無
- 滕威 無
- Rong-Nan Chien 無
- Chun-Yen Lin 無
- Chien-Hao Huang 無
- Yi-Chung Hsieh 無
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 楊宏志 無
- 蘇東弘 無
- Jia-Horng Kao 無
- 吳志宏 無
- PEI-JER CHEN 無
- 曾岱宗 無
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 邱彥程 無
- 簡世杰 無
- Chiu Hung Chiu 無
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
130 participants
